Brain scans and a new drug combo aim to break the cycle of depressive rumination
NCT ID NCT06937476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding aripiprazole to the antidepressant escitalopram can reduce pathological rumination—repetitive, intrusive negative thoughts—in people with major depressive disorder. 108 participants will receive either escitalopram alone or escitalopram plus aripiprazole for 8 weeks. Brain scans before and after treatment will help researchers understand how dopamine activity relates to changes in rumination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aripiprazole (added to escitalopram)
What this could lead to
If it works, this could point toward a targeted treatment for repetitive negative thinking in depression, and help explain the brain chemistry behind it.
What could go wrong
This is a small, early-phase study (108 people) with no blinding for patients. The results may not apply to all populations, and the benefit of aripiprazole for rumination is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410011, China